Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size

Rebecca Faresjö, Gillian Bonvicini, Xiaotian T. Fang, Ximena Aguilar, Dag Sehlin and Stina Syvänen

Abstract

Background: Transferrin receptor (TfR1) mediated enhanced brain delivery of antibodies have been studied extensively in preclinical settings. However, the brain pharmacokinetics, i.e. brain entry, distribution and elimination are still not fully understood for this class of antibodies. The overall aim of the study was to compare the brain pharmacokinetics of two BBB-penetrating bispecific antibodies of different size (210 vs 58 kDa). Specifically, we wanted to investigate if the faster systemic clearance of the smaller non-IgG antibody di-scFv3D6-8D3, in comparison with the IgG-based bispecific antibody mAb3D6-scFv8D3, was also reflected in the brain.

Methods: Wild-type (C57/Bl6) mice were injected with 125I-iodinated (125I) mAb3D6-scFv8D3 (n = 46) or 125I-di-scFv3D6-8D3 (n = 32) and euthanized 2, 4, 6, 8, 10, 12, 16, or 24 h post injection. Ex vivo radioactivity in whole blood, peripheral organs and brain was measured by γ-counting. Ex vivo autoradiography and nuclear track emulsion were performed on brain sections to investigate brain and parenchymal distribution. Capillary depletion was carried out at 2, 6, and 24 h after injection of 125I-mAb3D6-scFv8D3 (n = 12) or 125I-di-scFv3D6-8D3 (n = 12), to estimate the relative levels of radiolabelled antibody in brain capillaries versus brain parenchyma. In vitro binding kinetics for 125I-mAb3D6-scFv8D3 or 125I-di-scFv3D6-8D3 to murine TfR were determined by LigandTracer.

Results: 125I-di-scFv3D6-8D3 showed faster elimination from blood, lower brain Cmax and Tmax, a larger parenchymal-capillary concentration ratio, and a net elimination from brain at an earlier time point after injection compared with the larger 125I-mAb3D6-scFv8D3. However, the elimination rate from brain did not differ between the antibodies. The study also indicated that 125I-di-scFv3D6-8D3 displayed lower avidity than 125I-mAb3D6-scFv8D3 towards TfR1 in vitro and potentially in vivo, at least at the BBB.

Conclusion: A smaller size and lower TfR1 avidity are likely important for fast parenchymal delivery, while elimination of brain-associated bispecific antibodies may not be dependent on these characteristics.

Keywords: Bispecific antibody, Brain pharmacokinetics, Transferrin receptor, BBB

Background

The market for biological drugs such as peptides, proteins and monoclonal antibodies (mAbs), is growing in parallel to traditional small molecule drugs. Within the field of oncology and autoimmune diseases, the use of therapeutic mAbs has advanced rapidly in the last decade. However, biological drugs for brain diseases face the problem of very limited brain uptake due to their large size and polarity. We have shown in multiple studies using...
radiolabelled antibodies that less than 0.05% of the initial dose is found in the brain 2 h after i.v. or i.p. injection [1–4]. The brain access of antibodies is mainly restricted by the blood–brain barrier (BBB), a highly regulated unit of endothelial-cell tight junctions, pericytes and astrocytic end-feet [5]. Transport from the blood into the brain via the cerebrospinal fluid (CSF) is also indirectly restricted by the blood-cerebrospinal fluid barrier at the epithelium of the choroid plexus [6]. Despite the low brain penetration of mAbs, immunotherapies are being explored for central nervous system (CNS) diseases. For neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), only symptomatic treatment is presently available. Antibodies have been investigated as potential disease modifying immunotherapeutic treatments for AD and PD, and some have reached advanced clinical trials [7, 8]. Due to difficulties measuring brain parenchymal concentrations of drugs, CSF is often used as a surrogate for brain interstitial fluid (ISF). However, CSF-to-serum ratios for antibodies are likely to be higher than ISF-to-plasma ratios, and hence, reported brain uptake of antibodies may be overestimated [9, 10]. Increased brain penetrance of antibody-based therapies could potentially improve both efficacy and safety of immunotherapies for CNS disorders.

During the last decade, BBB penetrating biological molecules have been developed. One of the most widely used strategies includes receptors expressed at the BBB for receptor-mediated transcytosis (RMT) of macromolecules. The insulin receptor and transferrin receptor 1 (TfR1) are the most studied RMT systems [11]. Transferrin receptor mediated transcytosis has been studied for antibodies in various formats, and has been found to be very efficient for increasing brain uptake of antibodies [1, 9, 12–17]. Antibodies are complex macromolecules, able to recognise and interact with targets in a highly specific way. They are also easily engineered into unnaturally existing formats including bispecific targeting. We have previously studied the brain distribution of different variants of mAb158, an antibody directed against soluble aggregates of amyloid-beta (Aβ), conjugated to 8D3, an anti-mouse TfR1 antibody [18–20]. This conjugation increased brain concentrations of mAb158 significantly and radiolabelling of the bispecific antibody enabled imaging of intra-brain Aβ pathology by positron emission tomography (PET) and single photon emission computed tomography (SPECT) in transgenic mice overexpressing Aβ [1, 14, 21–24].

With emerging therapies based on brain-penetrating antibodies and antibody fragments, there is an urgent need to understand the mechanisms responsible for their brain entry, intrabrain distribution, and clearance. In general, the pharmacokinetics of macromolecules in the brain is not yet well understood. It has been shown that macromolecules in the CSF can access the extracellular spaces at the brain surface by diffusion, and further, that macromolecules can be transported by convection via the perivascular spaces (PVS) of blood vessels and microvasculature to access deeper brain regions [25]. Potentially, perivascular transport also allows parenchymal access in conjunction to the microvasculature of the brain, where exchange is thought to occur from peri-arterial to peri-venous capillaries via diffusion across the parenchyma [25, 26]. Antibodies designed for brain TfR1-mediated transcytosis by fusion of a TfR1-binding moiety to the original IgG antibody enter the parenchyma primarily through the endothelial cells of the BBB. These bispecific antibodies have been shown to access the brain to a higher extent and to be more uniformly distributed inside the brain compartment and parenchyma compared with unmodified IgG antibodies [4, 21]. However, the size of the antibody construct could impact its ability to diffuse within the limited space between the cells of the parenchyma. For example, brain distribution from the CSF was shown to be size-dependent when comparing a 15 kDa single domain antibody (sdAb) and an 150 kDa IgG antibody, where the former, smaller antibody showed a more diffuse and deeper distribution into the parenchyma [25]. However, there is a general lack of knowledge regarding how size and other factors may influence the transport processes and intrabrain distribution after systemic administration of antibody drugs, including antibodies that enter the brain via TfR1 mediated BBB transcytosis.

In this paper, we compared the brain pharmacokinetics of two bispecific TfR1-binding antibodies (Fig. 1) during the first 24 h after administration in wild-type mice. These bispecific antibodies were based on 3D6, the murine version of the Aβ-targeting antibody bapineuzumab, and 8D3, the TfR1 rat-anti-mouse antibody [27]. The bispecific antibodies differed fourfold in size: mAb3D6-scFv8D3, a 210 kDa IgG-like fusion antibody and di-scFv3D6-8D3, a 58 kDa fusion of two single-chain variable fragments (scFv). The smaller antibody was initially developed to be used as an antibody-based PET-ligand and is characterised by a faster clearance from blood compared with antibody constructs based on full-sized IgGs [28, 29]. The faster systemic clearance can be explained by its smaller size and lack of an Fc region, which interacts with the neonatal Fc receptor (FcRn) that prolongs antibody residence time in blood by a recycling mechanism [30]. In the present study, we asked if the faster systemic clearance of di-scFv3D6-8D3 is also
reflected in the brain, and compared its brain pharmacokinetics with the brain pharmacokinetics of the larger IgG-like construct, mAb3D6-scFv8D3.

We show that the two bispecific antibodies differ in apparent brain pharmacokinetic behaviour and propose possible reasons for this.

**Methods**

**Recombinant expression and purification of bispecific antibodies**

The two bispecific antibodies, mAb3D6-scFv8D3 and di-scFv3D6-8D3, were cloned, expressed and purified by affinity chromatography according to previously published protocols [1, 28, 31]. Additionally, to improve the purity of di-scFv3D6-8D3, a polishing step was added by using ion exchange chromatography (IEX) on a 1 ml HiTrap SP column (GE Healthcare, Uppsala Sweden) with 50 mM HEPES as binding buffer (ionic strength 0.008 M, pH 7.0), and eluted in the same buffer with the addition of a NaCl gradient up to 0.5 M. The size and purity was determined by SDS-PAGE (see Additional file 1: Fig. S1).

**Radiochemistry**

The two bispecific antibodies, mAb3D6-scFv8D3 and di-scFv3D6-8D3, were radiolabelled by direct iodination with iodine-125 ($^{125}$I) using the Chloramine-T method [32]. In short, mAb3D6-scFv8D3, or di-scFv3D6-8D3, was mixed with $^{125}$I stock solution (Perkin-Elmer Inc Waltham, MA, USA) and 5 μg Chloramine-T (Sigma Aldrich, Stockholm, Sweden) in PBS to a final volume of 110 μl. The reaction was incubated for 90 s at room temperature, and then quenched with 10 μg sodium metabisulfite (Sigma Aldrich). The product was diluted to 500 μl with PBS, and separated from free-iodine and low molecular weight products with a NAP-5 size exclusion column (GE Healthcare, Uppsala, Sweden) with a total elution volume of 1 ml PBS.

**In vitro validation of radiolabelled bispecific antibodies**

ELISA was performed as an in vitro quality control in order to assess the potential effect of radiolabelling on mAb3D6-scFv8D3 and di-scFv3D6-8D3. Indirect ELISA was used to measure mAb3D6-scFv8D3 and di-scFv3D6-8D3 binding to Aβ$_{42}$ before and after $^{125}$I-iodination, as described previously [14]. For murine TfR1 (mTfR1) binding before and after radiolabelling, indirect ELISA was used for di-scFv3D6-8D3 and a competition ELISA was used for mAb3D6-scFv8D3 and a competition ELISA was used for di-scFv3D6-8D3 [1]. All of the ELISA setups are described in more detail in the Additional file 1: Figs. S2 and S3.

**LigandTracer-based real-time binding kinetics assay**

Binding to mTfR1 was also investigated after iodine radiolabelling with LigandTracer (Ridgeview Instruments AB, Uppsala, Sweden). A small circular area in a high binding petri dish was coated with 200 nM of mTfR1 (BioArctic AB, Stockholm, Sweden) and incubated overnight at 4 °C. The plate was blocked with 5% BSA for 1 h at room temperature. The blocking buffer was replaced with 3 ml of 0.1% BSA solution and the plate was placed in a LigandTracer Grey instrument (Ridgeview Instruments AB) for a 10 min baseline measurement at room temperature. Two association phases were then measured: first with 2 nM of $^{125}$I-labelled antibody for 3 h and the second with 6 nM of $^{125}$I-labelled antibody for 4 h. The association phases were then followed by a dissociation phase overnight.

Binding kinetics were analysed with TraceDrawer software version 1.8.1 (Ridgeview Instruments AB). $^{125}$I mAb3D6-scFv8D3 binding curves were analysed with a 1:1 binding model while $^{125}$I di-scFv3D6-8D3 binding curves were analysed with a 1:2 binding model.
Animals
Both male and female wild-type mice (C57/B6) at the age of 2.5–4 months were used for the ex vivo pharmacokinetic study \((n = 78)\) and for capillary depletion \((n = 24)\). The animals were housed in an approved animal facility at Uppsala University with ad libitum access to food and water. All described procedures were approved by the Uppsala Country Animal Ethics board (5.8.18–13350/2017) following the legislation and regulations of the Swedish Animal Welfare Agency and European Communities Council Directive of 22 September 2010 (20103/EU) (Table 1).

Ex vivo study of \(^{125}\)I-iodinated bispecific antibodies
The molar activities attained after \(^{125}\)I-iodination of the antibodies were \(90 \pm 7\) MBq/nmol for \([^{125}\text{I}]\text{mAb3D6-scFv8D3}\) and \(97 \pm 9\) MBq/nmol for \([^{125}\text{I}]\text{di-scFv3D6-8D3}\), respectively. Mice were intravenously (i.v.) injected in the tail vein with either \(0.40 \pm 0.11\) MBq \([^{125}\text{I}]\text{mAb3D6-scFv8D3}\) (0.09 mg/kg) \((n = 46)\) or \(0.52 \pm 0.14\) MBq \([^{125}\text{I}]\text{di-scFv3D6-8D3}\) (0.02 mg/kg) \((n = 32)\). Blood samples \((8 \mu\text{L})\) were obtained from the tail vein of selected individuals at 1, 2, 4, 6, 8 and 10 h to investigate the concentration profile in blood. At 2, 4, 6, 8, 10, 12, 16 or 24 h after administration of radiolabelled antibody, mice were anaesthetized with isoflurane and a terminal blood sample was taken from the heart, followed by transcordial perfusion with 40 ml of 0.9% NaCl for 2.5 min to clear the brain and organs of blood. Thereafter, lung, liver, kidney, whole heart, pancreas, spleen, femoral muscle, femoral bone, skull bone and submandibular glands were isolated to investigate the biodistribution of the radiolabelled antibodies. The brain was divided into left and right hemispheres, and the left hemisphere was further divided into cerebrum and cerebellum. The brain samples were immediately frozen at \(-80^\circ\text{C}\). The radioactivity of all samples was measured with a \(\gamma\)-counter (2480 Wizard™, Wallac Oy PerkinElmer, Turku, Finland). Antibody concentrations were expressed as percent of injected dose per gram tissue \((\%\text{ID/g})\) or percent of injected dose corrected for body weight \((\text{bw})\) of the animal \((\%\text{ID/g/bw})\).

\[
\%\frac{\text{ID}}{g} = \frac{\text{measured radioactivity per gram tissue}}{\text{total injected radioactivity}} \quad (1)
\]

\[
\%\frac{\text{ID}}{\text{bw}} = \frac{\text{measured radioactivity per gram tissue}}{\text{total injected radioactivity per gram animal}} \quad (2)
\]

Brain-to-blood ratio was calculated as:

\[
\text{Brain-to-blood ratio} = \frac{\text{Brain radioactivity per gram brain}}{\text{Blood radioactivity per gram blood}} \quad (3)
\]

The pharmacokinetic parameter estimates were based on ex vivo measured radioactivity in the cerebrum of the left hemisphere. Autoradiography, immunofluorescence and nuclear track emulsion were performed on brain sections prepared from the right hemisphere.

Pharmacokinetic parameter estimates
Estimation of whole blood half-lives was done in Prism 8 software (GraphPad Software, Inc., La Jolla, CA, USA) using nonlinear regression with a two-phase decay model. The plateau was constrained to zero and \(Y_0\) was fixed to 50% for both antibodies, assuming an average mouse blood volume of 2 ml [33]. The fast and slow half-life blood for \([^{125}\text{I}]\text{mAb3D6-scFv8D3}\) could be estimated using 95% confidence intervals, while 90% confidence intervals were used for \([^{125}\text{I}]\text{dis-cFv3D6-8D3}\). The same software was used for the brain half-life estimates using nonlinear regression, and the “plateau followed by one phase decay” model to estimate the half-life during

Table 1 The total number of animals administered \([^{125}\text{I}]\text{mAb3D6-scFv8D3}\) or \([^{125}\text{I}]\text{di-scFv3D6-8D3}\), respectively, with the capillary depletion animals included in brackets.

| Euthanization time (h) post administration | No. of individuals (n) administered \([^{125}\text{I}]\text{mAb3D6-scFv8D3}\) (capillary depletion animals) | No. of individuals (n) administered \([^{125}\text{I}]\text{di-scFv3D6-8D3}\) (capillary depletion animals) |
|-----------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| 2                                             | 6 (+4)                                           | 4 (+4)                                           |
| 4                                             | 4                                               | 4                                               |
| 6                                             | 6 (+4)                                           | 4 (+4)                                           |
| 8                                             | 7                                               | 4                                               |
| 10                                            | 6                                               | 4                                               |
| 12                                            | 6                                               | 4                                               |
| 16                                            | 5                                               | 4                                               |
| 24                                            | 6 (+4)                                           | 4 (+4)                                           |
| Total                                         | 46 (+12)                                         | 32 (+12)                                         |
Radioactivity

NaH2PO4, 10 mM D-glucose adjusted to pH 7.4) with 6 strokes in an ice cold Dounce homogeniser. Thereafter the fractions was measured in a γ-counter (PerkinElmer) for 20 min at 4 °C. The centrifugation resulted in a parenchymal supernatant with a layer of fat, and a capillary enriched pellet which was carefully separated from the supernatant. The activity of the fractions was measured in a γ-counter (PerkinElmer) and the radioactive signal for each fraction was normalised to the injected dose (%ID) in MBq.

%ID = \frac{\text{Radioactivity}_{\text{fraction}}}{\text{Injected radioactivity}}. \quad (5)

Within blood distribution

In addition to the BBB, TFR1 is expressed peripherally, e.g. to a high extent on immature red blood cells [34]. This can potentially affect the pharmacokinetics of bispecific antibodies. Therefore, the antibody concentration in plasma versus blood cells was investigated at the different terminal time points.

The terminal blood sample was placed in an Eppendorf tube prepared with heparin. The tube was centrifuged for 5 min at 10,000×g at 4 °C. Plasma was carefully separated from the blood cells by aspiration, and radioactivity in the separated fractions was measured with a γ-counter (PerkinElmer). The percentage of radioactivity in plasma was calculated by:

% Plasma = \frac{\text{Radioactivity}_{\text{plasma}}}{\text{Radioactivity}_{\text{plasma}} + \text{Radioactivity}_{\text{blood cells}}} \quad (4)

Capillary depletion

Capillary depletion was performed on perfused mice euthanized 2, 6 or 24 h post injection of [125I]mAb3D6-scFv3D6 (injected dose: 0.11 ± 0.06 MBq) or [125I]di-scFv3D6-8D3 (injected dose: 0.56 ± 0.03 MBq). The number of animals was four per time point and antibody (total n = 24). The capillary depletion procedure was done as previously described [35, 36], with modifications as described below. Brain cortices were isolated immediately after transcardial perfusion. The cortices were weighed and homogenised in 0.8 ml cold physiological buffer (10 mM HEPES, 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2, 1 mM MgSO4, 1 mM NaH2PO4, 10 mM D-glucose adjusted to pH 7.4) with 6 strokes in an ice cold Dounce homogeniser. Thereafter, 1.6 ml of 30% Ficoll 400 (Sigma Aldrich) was added followed by an additional stroke. The homogenate was transferred to a 15 ml Falcon tube, which was centrifuged at 5200×g for 20 min at 4 °C. The centrifugation resulted in a parenchymal supernatant with a layer of fat, and a capillary enriched pellet which was carefully separated from the supernatant. The fractions were investigated under light microscopy with trypan blue staining to confirm enrichment of capillaries in the pellet and capillary depletion in the parenchymal supernatant. The activity of the fractions was measured in a γ-counter (PerkinElmer) for 20 minutes at 4 °C. The centrifugation resulted in a parenchymal supernatant with a layer of fat, and a capillary enriched pellet which was carefully separated from the supernatant. The activity of the fractions was measured in a γ-counter (PerkinElmer)

Ex vivo Autoradiography

The frozen right hemispheres were sectioned sagittally (20 μm) in a cryostat (CM1850, Leica Biosystems, Nussloch, Germany) and mounted on glass slides. Duplicate sections from each animal together with a standard of 125I with known radioactivity were exposed to a phosphor imaging plate (MS, Multisensitive, PerkinElmer, Downers Grove, IL, USA) for 7 days. The plates were scanned in a Cyclone Plus phosphor imager (PerkinElmer) at 600 dots per inch. The generated digital image was converted with a lookup table (Royal) in ImageJ. The radioactivity standards were used to normalise intensities for images obtained from different plates (see Additional file 1: Fig. S4).

Immunofluorescence CD31-staining

Adjacent sagittal brain cryosections to the autoradiography sections described above, were fixed in ice-cold MeOH for 10 min and then washed in PBS. The sections were blocked for 1 h with 5% Normal Goat Serum, washed in PBS, followed by a wash in 0.1% Tween-20 in PBS for 5 min. 1.25 μg/ml of the primary antibody rat-anti-mouse CD31 (BD, #553370), was applied to the sections and incubated overnight at 4 °C with slow shaking. After incubation, the sections were washed in PBS and 10 μg/ml secondary antibody goat-anti-rat (Alexa 555 or Alexa 647) was added for 1 h with slow shaking, followed by another PBS wash. The sections were stored in PBS until the nuclear track emulsion procedure (described below) was performed on the same day.

Nuclear track emulsion

Nuclear track emulsion (NTE) allows visualisation of radionlabelled molecular compounds as silver grains on top of immuno-stained sections. NTE experiments were done in darkness, as previously described [21]. In brief, ILFORD K5 emulsion (Oxford Instruments, Gometz la Ville, France) was prepared in a 40 °C water bath as a 50:50 emulsion in MQ-water. The CD31-stained sections were immersed in the emulsion for 10 s. The sections were left to air dry for 2 h, before they were incubated in dark conditions for 5 weeks at 4 °C. The sections were developed according to the manufacturer’s instructions, then dehydrated in increasing EtOH concentration gradient (70%, 95%, 100%) and mounted with Pertex (Histolab). Images of the developed emulsion and CD31-immunofluorescent stained sections were acquired with
a Zeiss Observer Z.1 microscope (Carl Zeiss Microimaging GmbH, Jena, Germany) and processed equally using the ZEN software. An alternative version of Fig. 7a, b, can be found in the supplementary material with colors converted by the function “Selective Color” in Photoshop, to show silver grains in white on a dark background (Additional file 1: Fig. S6).

**Image quantification**

The percentage area of NTE-signal associated with capillary and parenchymal regions was quantified with Fiji (ImageJ) using 18–20 images per time point (1–2 individuals per time point). A standardized macro was used to process 10 sets of images from each individual at a time.

In short, rolling ball background subtraction was applied to all images. The standardized macro used pre-defined processing and thresholds to create binary images with separate signal thresholds for capillaries (CD31-image) and nuclear track emulsion (NTE-image). The total area of regions of interest (ROIs) in the NTE-image were measured using “Analyse particles”, set to count ROIs of 2–200 pixels. Next, the “Image calculator” was used to subtract the corresponding CD31-ROIs from the image. This produced an image with NTE signal only in the non-capillary regions (parenchymal). NTE-image ROIs were measured again with “Analyse particles”, yielding a total area of NTE-signal in the parenchymal regions. The percentage area of NTE-signal in the parenchymal regions was calculated by dividing the total area after subtraction with the total area before subtraction × 100. Capillary signal was calculated by 1 – parenchymal signal. The accuracy of the ROIs was evaluated visually by using overlays on the original image, as shown in Additional file 1: Fig. S5.

**Statistical analysis**

Data is presented as mean ± standard deviation, if not stated otherwise. All calculations were made in Prism 8 (GraphPad Software, Inc.). The EC50 values for the ELISAs were calculated from agonist vs response curves, while the IC50 was calculated from the inhibitor vs response curves. A paired t-test was used to compare differences within the EC50 values or the IC50 values. The correlation between mean intensity of the ex vivo autoradiography and the injected dose per gram brain was evaluated with Pearson’s correlation coefficient. Two-way analysis of variance followed by Bonferroni’s post hoc test was used to test differences in plasma or capillary distribution between [125I]mAb3D6-scFv8D3 and [125I]di-scFv3D6-8D3 at the different time points.

**Results**

**Size and purity assessed by SDS-PAGE**

The size and purity of mAb3D6-scFv8D3 and di-scFv3D6-8D3 was analysed by SDS-PAGE under non-reducing conditions. The SDS-PAGE gels showed bands at the expected size around 210 kDa for mAb3D6-scFv8D3 and 58 kDa for di-scFv3D6-8D3. The di-scFv3D6-8D3 preparation contained less impurities in the higher molecular weight range after HiTrap-IEX purification (Additional file 1: Fig. S1).

**In vitro affinity after radiolabelling**

The antibodies retained binding to the antigens after radiolabelling. The Aβ ELISA showed no difference between radiolabelled and non-radiolabelled antibody. The mTfR1 ELISA indicated that the affinity of the radiolabelled antibody was on average twofold lower than the non-radiolabelled version. However, none of the differences were statistically significant (n = 3 repetitions for all assays) (Additional file 1: Figs S2 and S3).

The LigandTracer indicated a fivefold stronger binding of [125I]mAb3D6-scFv8D3 to mTfR1 compared with [125I]di-scFv3D6-8D3 based on the KD1 estimates (Table 2).

A 1:1 model was fitted to the [125I]mAb3D6-scFv8D3 LigandTracer data, whereas a 1:2 model proved to be the best fit for the [125I]di-scFv3D6-8D3 data (Fig. 2).

**Pharmacokinetics in blood**

Analysis of whole blood samples showed that [125I]di-scFv3D6-8D3 displayed faster elimination from whole blood than [125I]mAb3D6-scFv8D3, both in the fast and in the slow phase (Fig. 3a; Table 3). The total whole blood exposure, AUCblood(2–24 h), was 2-fold higher for [125I]mAb3D6-scFv8D3 compared with [125I]di-scFv3D6-8D3 (Table 3).

| Ligand          | Model | Bmax 1 (norm %) | k11 (1/Ms) | k11 (1/s) | KD1 (M) | k12 (1/Ms) | k12 (1/s) | KD2 (M) |
|-----------------|-------|-----------------|------------|-----------|---------|------------|-----------|---------|
| [125I]mAb3D6-scFv8D3 | 1:1   | 98.73 ± 2.37    | 3.73 x 10^4 ± 7.75 x 10^3 | 1.91 x 10^-6 ± 1.01 x 10^-6 | 5.38 x 10^-11 ± 2.92 x 10^-11 |
| [125I]di-scFv3D6-8D3  | 1:2   | 76.00 ± 3.66    | 2.02 x 10^4 ± 1.51 x 10^3 | 5.32 x 10^-6 ± 3.96 x 10^-7 | 2.65 x 10^-19 ± 1.39 x 10^-11 |
|                 | Bmax 2 (norm %) | k12 (1/Ms) | k12 (1/s) | KD2 (M) |
|                 | [125I]di-scFv3D6-8D3  | 1:2   | 73.14 ± 26.87 | 5.74 x 10^-4 ± 2.92 x 10^-4 | 3.61 x 10^-14 ± 2.98 x 10^-15 | 7.55 x 10^-9 ± 3.78 x 10^-9 |

Association rate constant, k1; dissociation rate constant, k2; equilibrium dissociation constant, KD. Values are reported as mean ± standard deviation (n = 3)
The mean brain concentrations for \([^{125}\text{I}]\text{mAb3D6-scFv8D3}\) and \([^{125}\text{I}]\text{di-scFv3D6-8D3b}\) at 2 h post injection were 1.1 ± 0.23%ID/g\_brain and 0.76 ± 0.06%ID/g\_brain, respectively. Both antibodies had increased brain uptake in comparison to unmodified IgGs which have a reported brain concentration of ~0.03%ID/g\_brain using a similar experimental set-up [1, 4]. The brain exposure over time, quantified as AUC\_brain(2–24 h), was 2-fold higher for \([^{125}\text{I}]\text{mAb3D6-scFv8D3}\) compared with
Table 3 Whole blood half-lives for the fast and slow phase and AUCblood(2–24 h) for [125I]mAb3D6-scFv8D3 and [125I]di-scFv3D6-8D3

| Ligand                        | Half-life (fast) | Half-life (slow) | AUCblood(2–24 h) |
|-------------------------------|-----------------|-----------------|------------------|
| [125I]mAb3D6-scFv8D3          | 0.3 h (0.3–0.4) | 6.1 h (5.7–6.6) | 95.2 (85.4–104.9) |
| [125I]di-scFv3D6-8D3          | 0.2 h (0.2–0.3) | 5.2 h (4.5–6.1) | 53.7 (46.2–61.1)  |

The confidence intervals shown in brackets (CI95% and aCI90%).

Table 4 Estimated brain half-lives, AUCbrain(2–24 h) and observed brain Tmax, of %ID/g brain for [125I]mAb3D6-scFv8D3 and [125I]di-scFv3D6-8D3

| Ligand                        | Half-lifebrain (h) | AUCbrain(2–24 h) | Tmax (h) |
|-------------------------------|--------------------|-----------------|---------|
| [125I]mAb3D6-scFv8D3          | 8.1 (5.7–11.9)     | 18.1 (16.0–20.1) | 8       |
| [125I]di-scFv3D6-8D3          | 8.5 (6.8–11.0)     | 8.8 (7.9–9.7)    | 4       |

The confidence intervals are shown in brackets (CI95%).

[125I]di-scFv3D6-8D3 (Table 4). Brain-to-blood ratio for [125I]di-scFv3D6-8D3 diverged from [125I]mAb3D6-scFv8D3 after 12 h post administration and remained higher than the brain-to-blood ratio of the larger bispecific antibody for the following 12 h (Fig. 3b). Interestingly, [125I]mAb3D6-scFv8D3 displayed high and stable brain concentrations during the first 8 h post injection, with Tmax(brain) occurring around 8 h, followed by a net elimination phase (Fig. 3c, d). The smaller antibody, [125I]di-scFv3D6-8D3, displayed an earlier Tmax(brain) around 4 h post administration, but when corrected for body weight, the Tmax(brain) of [125I]di-scFv3D6-8D3 appeared to occur already at 2 h. Overall, [125I]di-scFv3D6-8D3 elimination from brain began earlier than [125I]mAb3D6-scFv8D3 elimination. However, once brain concentrations started to decrease, the brain half-life was similar for both [125I]mAb3D6-scFv8D3 and [125I]di-scFv3D6-8D3 (Fig. 3c, d; Table 4).

Parenchymal versus capillary distribution

Capillary depletion of brain homogenates showed that the distribution between the capillary enriched fraction and parenchymal fraction differed between the antibodies over time (Fig. 6). [125I]mAb3D6-scFv8D3 was found to a higher degree in the capillary enriched fraction than [125I]di-scFv3D6-8D3 for all time points and was significantly higher at 6 h (p < 0.01). The amount of [125I]mAb3D6-scFv8D3 in the capillary enriched fraction remained high within the first 6 h post injection, but had decreased at 24 h. On the contrary, the [125I]di-scFv3D6-8D3 capillary enriched fraction continually decreased over time (Table 5).

Peripheral biodistribution

Distribution of the two ligands to peripheral organs was higher overall for [125I]mAb3D6-scFv8D3 compared with [125I]di-scFv3D6-8D3. Especially liver and spleen displayed higher uptake of [125I]mAb3D6-scFv8D3 compared with [125I]di-scFv3D6-8D3 (Fig. 4).

The majority of the antibody molecules in whole blood were associated with blood cells rather than with plasma. On average, 72 ± 7% of [125I]mAb3D6-scFv8D3 and 63 ± 7% of [125I]di-scFv3D6-8D3 was found in the blood cell fraction over the course of the experiment. Thus, [125I]di-scFv3D6-8D3 showed higher relative concentrations in plasma compared with [125I]mAb3D6-scFv8D3, although the differences were not significant (Fig. 5).
di-scFv3D6-8D3 after correction for capillary-parenchyma distribution (Fig. 7d, e).

Discussion

In this study, we compared the brain pharmacokinetics of two radiolabelled bispecific antibodies, the IgG-like $^{[125]}$I mAb3D6-scFv8D3 fusion antibody and the non-IgG-like tandem construct of two antibody-single-chain variable fragments, $^{[125]}$I di-scFv3D6-8D3.

The smaller $^{[125]}$I di-scFv3D6-8D3 displayed faster elimination from blood when compared with $^{[125]}$I mAb3D6-scFv8D3, confirming that a smaller bispecific antibody construct, lacking an Fc domain, is associated with faster pharmacokinetic processes [28]. The level of exposure was 2-fold lower both in blood (AUC$_{\text{blood}(2-24\,\text{h})}$) and in brain (AUC$_{\text{brain}(2-24\,\text{h})}$) for $^{[125]}$I di-scFv3D6-8D3, thus the faster blood clearance of $^{[125]}$I di-scFv3D6-8D3 was reflected in the brain by a proportionally lower brain exposure. In addition, peak antibody concentration in brain was observed earlier for $^{[125]}$I di-scFv3D6-8D3 compared with $^{[125]}$I mAb3D6-scFv8D3. Interestingly once the brain net elimination
phase was initiated, the rate of elimination from brain was similar for both antibodies.

One reason for the delayed elimination phase from brain for \(^{[125]}\)mAb3D6-scFv8D3, in comparison with \(^{[125]}\)di-scFv3D6-8D3, is likely the higher degree and prolonged association with brain capillaries throughout the study period for \(^{[125]}\)mAb3D6-scFv8D3. Although \(^{[125]}\)mAb3D6-scFv8D3 showed higher total brain concentrations than \(^{[125]}\)di-scFv3D6-8D3 in general, a larger fraction of \(^{[125]}\)mAb3D6-scFv8D3 was retained in the capillaries as shown with both capillary depletion and nuclear track emulsion. These two radically different methods led to very similar results regarding the relative antibody distribution between capillaries and parenchyma. Although the total concentrations of \(^{[125]}\)di-scFv3D6-8D3 in the brain was overall lower, the smaller antibody appeared to a higher relative degree in the parenchyma. This could be due to a more efficient transcytosis across the BBB compared with \(^{[125]}\)mAb3D6-scFv8D3 and in fact, when corrected for the capillary-parenchyma partitioning, the two antibodies reached similar parenchymal concentrations 2 h post injection. The high association of \(^{[125]}\)mAb3D6-scFv8D3 to capillaries could be a result of the higher blood exposure of \(^{[125]}\)mAb3D6-scFv8D3, yielding to accumulation over time at the capillaries. However, previous studies have showed that higher affinity to mTfR1 has been linked to poorer transcytosis [17, 37]. Perhaps more importantly in this study, binding mode and the avidity, i.e. the product of the affinity of all interactions between the antibody and the target, could explain the differences observed in capillary association. The larger antibody is by design bivalent, as it contains two scFv3D6 fragments, but previous in vitro studies have shown that the large antibody format is sterically hindered from bivalent interactions with TfR [1]. In contrast, in vitro real time kinetic binding curves obtained from the LigandTracer in the present study indicated a fivefold higher \(K_D\) of \(^{[125]}\)mAb3D6-scFv8D3 compared with \(^{[125]}\)di-scFv3D6-8D3 towards mTfR1. This discrepancy is perhaps due

---

**Table 5** Distribution between parenchymal and capillary enriched fraction (%)

|          | Parenchyma  | Capillary  | Parenchyma  | Capillary |
|----------|-------------|------------|-------------|----------|
| \(^{[125]}\)mAb3D6-scFv8D3 | 63 ± 12%   | 37 ± 12%   | 79 ± 4%     | 21 ± 4%   |
| \(^{[125]}\)di-scFv3D6-8D3 | 63 ± 5%    | 37 ± 5%    | 88 ± 3%     | 12 ± 3%   |
|          | 79 ± 9%     | 21 ± 9%    | 94 ± 2%     | 6 ± 2%    |

Values are shown as mean ± standard deviation
to assessment of the TfR-antibody interaction at higher concentrations in this study compared to previously. We speculate that, at high TfR1 concentrations, as in the LigandTracer analyses, a portion of \( {[^{125}I]} \)mAb3D6-scFv8D3 could simultaneously interact with two TfR molecules. Potentially, such interactions occur to some extent also in vivo, and could contribute to the observed differences in pharmacokinetic behaviour between \( {[^{125}I]} \)mAb3D6-scFv8D3 and \( {[^{125}I]} \)di-scFv3D6-8D3 at the BBB. Bivalent interactions have been reported to trigger clustering of the TfR-antibody complex and lysosome sorting within the endothelial cells [13, 38]. Interestingly, the antibodies displayed only a minor difference in distribution between blood cells and plasma. We speculate that TfR1 expression could be different on blood and endothelial cells, and thus, avidity could contribute to a stronger binding at the BBB but not at TfR1 expressing blood cells.

Both antibodies displayed initial brain concentrations around 1% ID/g brain which is about 30-fold higher than what has been reported for radiolabelled unmodified IgGs [1–4, 39]. Both antibodies also bound to TfR1 and human Aβ. However, since only wild-type mice were used in the present study, the impact of in vivo interaction with Aβ, for example in capillaries, is absent. Therefore, the brain
pharmacokinetics studied here are likely to be relevant for other TR1 binding antibodies, including bispecific antibodies directed towards other intra-brain targets. The rationale for using Aβ-binding bispecific antibodies was that a number of different Aβ-binding formats have been studied during the last 10 years, thus being the most frequently used application for brain penetrating bispecific antibodies [1, 9, 13, 23, 24, 40].

Despite different C_{max} and T_{max}, the antibodies in this study showed similar rates of clearance during the elimination phase. This suggests that the elimination route could be the same for both antibodies. One obvious option would be reverse TR1 transcytosis as suggested for transferrin, the endogenous ligand of the receptor [41]. However, since the antibody concentration is very low in the brain it is unlikely that this would be a very efficient route of elimination. In addition, it is likely that there must exist mechanisms for antibody removal from the brain that are not dependent on TR1. Some studies propose the role of reverse transcytosis by the FcRn receptor for Fc-receptor binding antibodies [42], for example for the clearance of intracranially administered IgGs in rats [43]. If this efflux at the endothelium also applies to transcytosed bispecific IgGs, it could explain why there appeared to be a prolonged retention in the capillaries of [^{125}I]mAb3D6-scFv8D3. However, since [^{125}I]di-scFv3D6-8D3 lacks an Fc-region, this route fails to explain how this antibody was eliminated from the brain. Perhaps the most likely route suggested for clearance of antibodies is via bulk flow to the lymphatic system [5, 44]. In 1981, Cserr and colleagues found that radiolabelled macromolecules injected in the rat brain were eliminated according to one phase elimination, with similar half-lives, despite large differences in molecular weight [45]. This supported convective bulk flow as the clearance pathway of large molecules from the brain, and the evidence for bulk flow elimination of large molecules has been discussed by others [5, 26, 44, 46]. This pathway of elimination for large molecules is consistent with the results from the present study. Radiolabelled albumin (69 kDa) injected in rat brain had a half-life in brain of 12.2 h, which is within a similar range as in the present study of two bispecific antibodies [45]. Antibodies in the parenchyma are likely transported via diffusion, but when reaching perivascular spaces the transport is mainly by bulk flow along the venous vasculature of the brain for clearance e.g. via the venous sinuses and deep cervical lymph nodes [26, 47]. A smaller format would likely be removed faster than a larger format by diffusion in the brain parenchyma, but at similar rate once reaching the bulk flow of the PVS [25, 26]. Additionally, the higher avidity of [^{125}I]mAb3D6-scFv8D3 to TR1 could cause prolonged association to and internalisation in parenchymal cells expressing TR1, such as neurons [9]. This could also have contributed to the slower brain elimination from parenchyma of the IgG-like antibody, after correction for capillary-parenchymal partitioning.

Pharmacokinetic studies based on radioligands benefit from the high sensitivity of radioactivity measurements, and thus, the minute amounts that can be detected and the very small sample volumes needed. However, if [^{125}I]di-scFv3D6-8D3 was degraded faster than [^{125}I]mAb3D6-scFv8D3 after internalisation into parenchymal cells, it could contribute to a higher parenchyma-to-capillary concentration ratio as free iodine will be eliminated to the intracellular space [48, 49]. On the other hand, deiodination and degradation would also be interpreted as removal of the antibody, and as discussed previously, elimination rate was similar for both antibodies. We have previously shown that iodine-125 radiolabelling is stable with very low levels of free iodine-125 in brain samples after antibody injection [3]. Still, it should be kept in mind that antibody and iodine-125 to some extent could be separate entities.

Conclusions
In summary, the smaller [^{125}I]di-scFv3D6-8D3 showed faster elimination from blood, a lower brain C_{max}, a lower brain T_{max}, a larger parenchyma-to-capillary concentration ratio, and a net elimination from brain at an earlier time point after injection compared with the larger [^{125}I]mAb3D6-scFv8D3. However, the elimination rate from brain did not differ between the antibodies. The study also indicated that [^{125}I]di-scFv3D6-8D3 displayed lower avidity than [^{125}I]mAb3D6-scFv8D3 towards TR1 in vitro and potentially in vivo, at least at the BBB. Thus, a small size and lower TR1 avidity seem to be important for fast and efficient parenchymal delivery, while elimination of brain associated bispecific antibodies may not be dependent on these characteristics.

Abbreviations
mAb: Monoclonal antibody; CSF: Cerebrospinal fluid; BBB: Blood–brain barrier; AD: Alzheimer’s disease; PD: Parkinson’s disease; ISF: Interstitial fluid; RMT: Receptor mediated transcytosis; mTR1: Mouse transferrin receptor 1; PVS: Perivascular space; sdAb: Single domain antibody; IgG: Immunoglobulin G; FcRn: Neonatal Fc-receptor; scFv: Single chain variable fragment; IEX: Ion exchange chromatography; NTE: Nuclear track emulsion; Aβ: Amyloid beta; PET: Positron emission tomography.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12987-021-00257-0.

Additional file 1. Fig. S1 a Non-reducing SDS-PAGE (4-12% Bis-Tris gel) of purified di-scFv3D6-8D3 and mAb3D6-scFv8D3. Lane 1 is protein ladder.
Acknowledgements

We would also like to acknowledge BioArctic for sharing the TIR protein, Jos Buijs for assistance with LigandTracer analyses, Sofia Gustafson for support in establishing the capillary depletion method, Greta Hultqvist for valuable input regarding the bispecific proteins and their expression and purification.

Authors’ contributions

RF, SS and DS designed the study. RF, SS and DS performed the in vivo experiments. RF and GB performed the in vitro experiments with the help of XTF and XA. RF performed the pharmacokinetic and image analysis. RF, SS and DS and GB analysed the results together. RF wrote the manuscript with feedback from all authors. All authors read and approved the final manuscript.

Funding

Open access funding provided by Uppsala University. This work was supported by grants from the Swedish Research Council (2017-02413 and 2018-02715), the Swedish Innovation Agency (2019-00106), Alzheimerfonden, Hjärnfonden, Stohnes Stiftelse, Magnus Bergvalls Stiftelse, Konung Gustaf V:s och Drottning Victorias stiftelse and AB, Warfinges väg 35, 112 51 Stockholm, Sweden. 2 BioArctic AB, Warfinges väg 35, 112 51 Stockholm, Sweden. 3 Department of Radiology and Biomedical Imaging, Yale University, Yale PET Center, 801 Howard Avenue, New Haven, CT 06520, USA.

Received: 19 February 2021 Accepted: 7 May 2021
Published online: 02 June 2021

References

1. Hultqvist G, Syvänen S, Fang XT, Lannfelt L, Sehlin D. Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics. 2017;7:308–18.
2. Magnusson K, Sehlin D, Syvänen S, Svedberg MM, Philipson O, Söderberg L, et al. Specific uptake of an amyloid-β protobifil-binding antibody-tracer in AβPP transgenic mouse brain. J Alzheimer Dis. 2013;37:29–40.
3. Sehlin D, Stocko P, Gustavsson T, Hultqvist G, Walsh FS, Rutkowski JL, et al. Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle. FASEB J. 2020;34:13272–83.
4. Syvänen S, Hultqvist G, Gustavsson T, Gumucio A, Laudon H, Söderberg L, et al. Efficient clearance of Aβ protobifils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody. Alzheimer Res Ther. 2018;10:49.
5. Abbott NJ, Rönnbäck L, Flensborg A, Porsteinsson A, Sabbagh M, Alzheimers Res Ther. 2017;9:53.
6. Lun MP, Monuki ES, Lehtinen MK. Development and functions of the choroid plexus–cerebrospinal fluid system. Nat Rev Neurosci Nat Publ Group. 2015;16:44–57.
7. Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M, Aducumanub, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near-term approval. Alzheimer Res Ther. 2020;12:95.
8. Zella SMA, Metzdorf J, Ciftci E, Ostendorf F, Muhleck S, Gold R, et al. Emerging immunotherapies for Parkinson disease. Neuronal Ther. 2018;8:29–44.
9. Kaniolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Hong T, et al. Brain delivery of therapeutic proteins using an Fc fragment blood–brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12(545):esa51359.
10. Lang M, Metzdorf J, Ciftci E, Ostendorf F, Muhleck S, Gold R, et al. Emerging immunotherapies for Parkinson disease. Neuronal Ther. 2018;8:29–44.
11. Johansen KB, Burkhart A, Thomsen LB, Andresen TL, Moos T. Targeting the transferrin receptor for brain drug delivery. Prog Neurobiol. 2019;181:101665.
12. Johansen KB, Bak M, Kenpen PJ, Melander F, Birkhaut A, Thomsen MS, et al. Antibody affinity and valency impact brain uptake of transferrin receptor-targeted gold nanoparticles. Theranostics. 2018;8:3416–36.
13. Nierstrasz J, Bathmann B, Collin L, Unck E, Sade H, Maier P, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81:49–60.
14. Sehlin D, Fang XT, Cato L, Antoni G, Lannfelt L, Syvänen S. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer’s disease. Nat Commun. 2016;7:10759.
15. Yu Y, Atwai JK, Zhang Y, Tong RK, Wilsdorf KR, Tan C, et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman pri-

Available data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

All animal experiments described in this study were approved by the Uppsala County Animal Ethics board (S 8:18-13350/2017), following the rules and regulations of the Swedish Animal Welfare Agency and complied with the European Communities Council Directive of 22 September 2010 (2010/63/EU).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Public Health and Caring Sciences, Uppsala University, Rudbeck Laboratory, Dag Hammarskjölds väg 20, 751 85 Uppsala, Sweden. 2 BioArctic AB, Warfinges väg 35, 112 51 Stockholm, Sweden. 3 Department of Radiology and Biomedical Imaging, Yale University, Yale PET Center, 801 Howard Avenue, New Haven, CT 06520, USA.
16. Fishman JB, Rubin JB, Handrahan JV, Connor JR, Fine RE. Receptor-mediated transcytosis of transferrin across the blood–brain barrier. J Neurosci. 1987;18:299–304.

17. Yu YJ, Zhang Y, Kennick M, Hoyte K, Luk W, Lu Y, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3:84ra44.

18. Boado RJ, Zhang Y, Wang Y, Pardridge WM. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng. 2009;102:1251–8.

19. Kissel K, Hamm S, Schulz M, Vecchi A, Garlanda C, Engelhardt B. Immunohistochemical localization of the murine transferrin receptor (TfR) on blood-tissue barriers using a novel anti-TfR monoclonal antibody. Histochem Cell Biol. 1998;110:63–72.

20. Englund H, Sehlin D, Johansson A-S, Nilsson LNG, Gellerfors P, Paulie S, et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem. 2007;103:334–43.

21. Gustavsson S, Syvänen S, O’Callaghan P, Sehlin D. SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-B antibody in a mouse model of Alzheimer’s disease. Transl Neurodegener. 2020;9:37.

22. Meier SR, Syvänen S, Huultqvist G, Fang XT, Roshanbin S, Lannfelt L, et al. Antibody-based in vivo PET imaging detects amyloid-B reduction in a transgenic mouse model after BACE-1 inhibition. J Nucl Med. 2018;59:1885–91.

23. Sehlin D, Fang XT, Meier SR, Jansson M, Syvänen S. Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-B. Sci Rep. 2017;7:17254.

24. Syvänen S, Fang XT, Huultqvist G, Meier SR, Lannfelt L, Sehlin D. A bispecific Trbody PET radioligand for visualization of amyloid-beta protofibrils—a new concept for neuroimaging. Neuroimage. 2017;148:65–63.

25. Pizzo ME, Wolak DJ, Kumar NN, Brunette E, Brunnequill CL, Hannocks M, et al. Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery. J Physiol. 2018;596:445–75.

26. Abbott NJ, Pizzo ME, Preston JE, Janigro D, Thorne RG. The role of brain barriers in fluid movement in the CNS. Is there a “glymphatic” system? Acta Neuropathol. 2018;135:387–407.

27. Miles LA, Crespi GA, Doughly L, Parker MW. Bapineuzumab captures the N-terminus of the Alzheimer’s disease amyloid-beta peptide in a helical conformation. Sci Rep. 2013;3:1302.

28. Fang XT, Huultqvist G, Meier SR, Antoni G, Sehlin D, Syvänen S. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain. Neuroimage. 2019;189:881–8.

29. Sehlin D, Syvänen S, MINC faculty. Engineered antibodies: new possibilities for brain PET? Eur J Nucl Med Mol Imaging. 2019;46:2848–58.

30. Roopencan DJ, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–25.

31. Fang XT, Sehlin D, Lannfelt L, Syvänen S, Huultqvist G. Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells. Biol Proced Online. 2017;19:11.

32. Greenwood FC, Hunter WM, Glover JS. The preparation of 131I-labelled human growth hormone of high specific radioactivity. Biochim J. 1963;89:114–23.

33. Mitruka BM, Rawlins HM. Clinical biochemical and hematological reference values in normal experimental animals. J Clin Pathol. 1979;32(1):96.

34. Hamidi A, Garcia dos Santos D, Lee C-N, Schranzhofer M, Ponka P. Role of heme in the regulation of transferrin receptor expression in erythroid cells. Blood. 2017;130:3495–3495.

35. Triguero D, Buciak J, Pardridge WM. Capillary depletion method for quantification of blood–brain barrier transport of circulating peptides and plasma proteins. J Neurochem. 1990;54:1882–8.